#Bioretec #Finland #Tampere #Rights Issue #RemeOs

Bioretec Ltd Launches New Rights Issue

On May 28, 2025, Bioretec Ltd, a pioneering Finnish medical device company, publicly announced the commencement of a rights issue aimed at enhancing its capital base while providing current shareholders the opportunity to acquire additional equity. This move is designed to allow for a more flexible growth trajectory as Bioretec seeks to expand its presence in the orthopedic market.

Overview of the Rights Issue

Bioretec proposes the issuance of up to 6,156,618 new shares at a subscription price of EUR 1.50 per share. The rights issue reflects a strategic decision to improve shareholder engagement by leveraging the existing shareholder base. This initiative not only raises necessary funds but also aligns the interests of the company with those of its investors.

The official Exemption Document associated with this rights issue has been prepared in accordance with the European regulations governing such activities. This documentation will be accessible on Bioretec's website and the Danske Bank A/S Finland Branch's site from June 4, 2025.

Important Details

The subscription period is set to commence on June 5, 2025, at 9:30 AM Finnish time and conclude on June 19, 2025, at 4:00 PM. Shareholders will also have the ability to trade their subscription rights on the Nasdaq First North Growth Market Finland between June 5 and June 12, 2025, offering them flexibility in managing their investment strategies.

An investor presentation will be made available on June 5, 2025, allowing potential and existing investors to gain better insights into the offering and the strategic vision behind it. This presentation aims to foster greater understanding and transparency.

The Role of Advisors

Bioretec has engaged Danske Bank A/S and DNB Carnegie Investment Bank AB to act as Joint Global Coordinators and Joint Bookrunners for this rights issue, ensuring that the process maintains high standards of financial governance and accessibility. Legal oversight is provided by Krogerus Attorneys Ltd for the company and Borenius Attorneys Ltd for the advisers. Additionally, Bravura Ltd has been appointed for communications advisory services, ensuring that investor communication is clear and effective throughout the offering period.

Bioretec's Commitment to Innovation

Bioretec is recognized for its commitment to developing biodegradable orthopedic implants, notably the RemeOs™ product line, which incorporates innovative materials to enhance surgical outcomes. The company is poised to address a growing market opportunity, with its products currently deployed in around 40 countries globally. Continued development of the RemeOs™ line is set to revolutionize bone fracture treatment by offering effective healing solutions without the need for surgical removal of implants.

Looking Ahead

Through this rights issue, Bioretec aims to not just reinforce its existing capital structure but also position itself aggressively within the global orthopedic trauma and spine market, valued at over USD 10 billion. This initiative is a pivotal step to achieve the company’s long-term financial goals while continuing to focus on the core mission of improving patient outcomes through innovative medical solutions.

In conclusion, Bioretec's rights issue reflects a proactive approach to ensure growth while maintaining shareholder confidence. Stakeholders are encouraged to participate in the subscription process and look forward to the future advancements that Bioretec aims to bring forth in the realm of orthopedic care.

For further inquiries on the rights issue or company information, contact the interim CEO Sarah van Hellenberg Hubar-Fisher or CFO Johanna Salko, whose details have been provided in the company's announcement.